Coronavirus: Immunotherapy

Department of Health and Social Care written question – answered on 27th July 2021.

Alert me about debates like this

Photo of Daisy Cooper Daisy Cooper Liberal Democrat Spokesperson (Education)

To ask the Secretary of State for Health and Social Care, what steps he is taking to assist the Medicines and Healthcare products Regulatory Agency to progress the licensing process for the REGEN-COV, Regeneron, monoclonal antibody treatment.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

The Medicines and Healthcare products Regulatory Agency’s (MHRA) licensing of therapeutics, including for REGEN-COV, is an independent process. The Therapeutics Taskforce encourages companies seeking approvals for COVID-19 therapeutics to provide the data the MHRA requires to ensure that their products are of acceptable quality, safety and efficacy. Approval can only be determined when the full data has been provided by the manufacturer and assessed by the MHRA.

Does this answer the above question?

Yes1 person thinks so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.